Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184071 | 0.99 | MEN1 (0.56) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| SCHEMBL5413556 | 0.92 | L3MBTL1 (0.57) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5779638 | 0.90 | SMN1; SMN2 (0.47) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1621693 | 0.89 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| Hydrochloric Acid SCHEMBL17611756 | 0.89 | FKBP1A (0.47) | MEN1KMT2ASMN1; SMN2SIGMAR1 | |
| SCHEMBL5752863 | 0.88 | L3MBTL1 (0.48) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7189733 | 0.88 | GPR119 (0.45) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| SCHEMBL1622710 | 0.88 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| Hydrochloric Acid SCHEMBL183705 | 0.88 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1CCR8L3MBTL1 | |
| SCHEMBL350213 | 0.88 | FKBP1A (0.47) | MEN1KMT2ASMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119392325-B | Cyanide-free gold plating solution for plating gold on micro blind holes and electroplating method | 深圳创智芯联科技股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119392325-A | Cyanide-free gold plating solution for plating gold on micro blind holes and electroplating method | 深圳创智芯联科技股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-110734393-B | Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride | 南京恒远科技开发有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-110734393-A | Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride | 南京恒远科技开发有限公司 | 2020-01-31 | — | — | CN | claimed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12509438-B2 | Pyrazole derivative | APTABIO THERAPEUTICS INC. (KR) | 2025-12-30 | — | — | US | disclosed |
| US-20250282778-A1 | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | MIRATI THERAPEUTICS INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12286431-B2 | Crystalline forms of a KRas G12C inhibitor | Mirati Therapeutics, Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12281113-B2 | Crystalline forms of a KRas G12C inhibitor | Mirati Therapeutics, Inc. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119392325-B | Cyanide-free gold plating solution for plating gold on micro blind holes and electroplating method | 深圳创智芯联科技股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119392325-A | Cyanide-free gold plating solution for plating gold on micro blind holes and electroplating method | 深圳创智芯联科技股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115348959-B | Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity | GT增益治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-0897303-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0897303-A4 | — | — | 1999-02-24 | — | — | EP | disclosed |
| WO-1997036605-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-4831029-A | SEDATIVES, TRANQUILIZERS | REITER JOZSEF (HU) | 1989-05-16 | — | — | US | disclosed |
| CN-87107643-A | CONDENSED CYCLIC TRIAZOLE DERIVATIVES | — | 1988-08-24 | — | — | CN | disclosed |
| US-4254116-A | ANALGESICS, ANTIDEPRESSANTS, NEUTRALIZING AGENTS | ABBOTT LABORATORIES (US) | 1981-03-03 | — | — | US | disclosed |
| US-RE29196-E | ANALGESICS AND TRANQUILIZERS | ABBOTT LABORATORIES (US) | 1977-04-26 | — | — | US | disclosed |
| US-3932432-A | Alkylphenyl benzopyranopyridines | ABBOTT LABORATORIES (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281113-B2 | Crystalline forms of a KRas G12C inhibitor | KRAS, NRAS, HRAS | SIGMAR1 4508/4885MEN1 506/4885KMT2A 1138/4885 |
| US-12509438-B2 | Pyrazole derivative | CBR3, NR3C2, NR3C1 | SIGMAR1 153/4885MEN1 3044/4885KMT2A 4419/4885 |
| US-12286431-B2 | Crystalline forms of a KRas G12C inhibitor | KRAS, NRAS, HRAS | SIGMAR1 4508/4885MEN1 506/4885KMT2A 1138/4885 |
| US-20250282778-A1 | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | KRAS, NRAS, HRAS | SIGMAR1 4508/4885MEN1 506/4885KMT2A 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.